8-K: Waters Corp. Unveils Strong Performance & Strategic BD Acquisition

Waters Corporation presented a robust financial outlook and detailed the strategic acquisition of BD's Biosciences and Diagnostic Solutions business at the J.P. Morgan Healthcare Conference, projecting significant value creation.

Summary

• Waters Corporation presented at the J.P. Morgan Healthcare Conference on January 12, 2026, highlighting its strong business performance and strategic initiatives.
• The company reported $3.1 billion in total revenue for the trailing twelve months (TTM) ended September 27, 2025, with a 59.0% gross margin and 30.4% adjusted operating margin.
• Free Cash Flow (FCF) was 24% of sales for the TTM ended September 27, 2025.
• Waters is acquiring Becton, Dickinson and Company's (BD) Biosciences and Diagnostic Solutions business (SpinCo), which generated $3.3 billion in GAAP revenue for FY 2025.
• The acquisition is expected to double Waters' total addressable market (TAM) to $40 billion and drive significant value creation through $200 million in cost synergies by Year 3 and $290 million in revenue synergies by Year 5.
• The combined entity projects industry-leading financial performance with superior revenue growth CAGR, adjusted EBIT margin expansion, and adjusted EPS growth from CY 2025E to 2030E compared to peers.

Sentiment

Score: 9

Explanation: The filing presents a highly positive outlook, emphasizing strong current performance, successful strategic execution, and significant value creation potential from a major acquisition. All key financial metrics and future projections are presented as outperforming peers or contributing substantially to growth. The tone is confident and forward-looking, despite the standard risk disclaimers.

Positives

• Achieved $3.1 billion in total revenue for the TTM ended September 27, 2025.
• Maintained a strong gross margin of 59.0% and an adjusted operating margin of 30.4% for the TTM ended September 27, 2025.
• Generated robust Free Cash Flow (FCF) at 24% of sales for the TTM ended September 27, 2025.
• Demonstrated industry-leading organic constant-currency growth, adjusted operating margin, and adjusted EPS growth compared to peers for the TTM ended September 27, 2025.
• Successfully executed a bold transformation plan since 2020, regaining commercial momentum and delivering pioneering innovation.
• Alliance iS sales grew 270% year-over-year, Xevo TQ Absolute sales grew 40% year-over-year, and MaxPeak chemistry sales grew 35% year-over-year for the first 9 months of 2025.
• Successfully entered high-growth adjacencies, with significant 2025E growth contributions from Bioseparations (+95bps), Bioanalytical Characterization (+70bps), and LC-MS into Dx (+95bps).
• Identified idiosyncratic growth drivers (GLP-1s, PFAS, Generics in India) contributing an estimated +$80 million in 2025E incremental revenue.
• The acquisition of BD's Biosciences and Diagnostic Solutions business is expected to double Waters' total addressable market (TAM) to $40 billion.
• The acquisition is projected to generate $200 million in cost synergies by Year 3 and $290 million in revenue synergies by Year 5, translating to $145 million in Adjusted EBITDA.
• The combined company is expected to achieve industry-leading financial outlooks, including superior revenue growth CAGR, adjusted EBIT margin expansion, and adjusted EPS growth from CY 2025E to 2030E.
• Over 80% of the combined company's revenue will come from iconic brands, and over 70% will be annually recurring.

Risks

• One or more closing conditions to the proposed transaction, including certain regulatory approvals, may not be satisfied or waived on a timely basis or at all.
• A governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the proposed transaction, or may require conditions, limitations, or restrictions.
• The required approval by Waters' stockholders may not be obtained.
• The proposed transaction may not be completed on the terms or in the timeframe expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty of the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including delays in completion or integration of businesses.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs.
• Evolving legal, regulatory, and tax regimes.
• Changes in general political, economic, regulatory, environmental, trade, and/or industry-specific conditions or volatility from tariffs.
• Actions by third parties, including government agencies.
• The risk that the anticipated tax treatment of the proposed transaction is not obtained.
• Greater than expected difficulty in separating SpinCo's business from BD's other businesses.
• Disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
• Other effects of the pendency of the proposed transaction on relationships with employees, customers, suppliers, or other counterparties.
• The credit ratings of the combined company may decline following the proposed transaction.
• The announcement or consummation of the proposed transaction may have a negative effect on the market price of Waters' and BD's capital stock or on their operating results.

Future Outlook

Waters Corporation anticipates continued strong instrument replacement dynamics and projects a 200bps+ annual core growth contribution from 2026 to 2030, driven by five idiosyncratic growth drivers including biologics, informatics, GLP-1s, PFAS, and India generics. The proposed acquisition of BD's Biosciences and Diagnostic Solutions business is expected to double Waters' total addressable market to $40 billion and result in industry-leading financial performance, including superior revenue growth CAGR, adjusted EBIT margin expansion, and adjusted EPS growth for the combined company from CY 2025E to 2030E.

Management Comments

• Executing from a Position of Strength.
• Significant Value Creation Opportunity Ahead.
• Industry-Leading Financial Outlook.
• We have successfully executed a bold transformation plan since 2020, regaining commercial momentum and delivering pioneering innovation.
• We expect more of the same in 2026, with continued strong instrument replacement dynamics and significant core growth contributions from key drivers.

Industry Context

The acquisition of BD's Biosciences and Diagnostic Solutions business positions Waters to significantly expand its presence in high-growth adjacencies within the life sciences and diagnostics industry. This move aligns with broader industry trends towards integrated solutions, leveraging Waters' expertise in separations and mass spectrometry with BD's strong channels and regulatory capabilities in clinical flow cytometry, molecular diagnostics, and microbiology. The combined entity aims to capitalize on growing markets such as bioseparations, bioanalytical characterization, and multiplex diagnostics, while also addressing emerging areas like GLP-1s and PFAS testing, indicating a strategic pivot towards higher-growth segments and comprehensive offerings.

Comparison to Industry Standards

• Waters' trailing twelve-month (TTM) organic constant-currency (CC) revenue growth for the period ended September 27, 2025, outperforms its peer average.
• Waters' TTM adjusted operating margin of 30.4% for the period ended September 27, 2025, is superior to its peer average.
• Waters' TTM adjusted EPS growth for the period ended September 27, 2025, exceeds its peer average.
• The combined Waters and BD Biosciences & Diagnostic Solutions entity is projected to achieve a revenue growth CAGR (CY 2025E-30E) that is higher than the peer average.
• The combined entity is projected to achieve adjusted EBIT margin expansion (CY 2025E-30E) that is higher than the peer average.
• The combined entity is projected to achieve adjusted EPS growth (Annualized CY 2025E-30E) that is higher than the peer average.
• The Diagnostics Solutions segment of the acquired BD business has a 700bps+ gross margin gap compared to a close peer, presenting a significant opportunity for improvement through closed system optimization, price optimization, and cost efficiency/volume leverage.

Legal Proceedings

• The forward-looking statements section mentions a risk of 'stockholder litigation in connection with the proposed transaction or other litigation, settlements or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification and liability.'

Stakeholder Impact

• Shareholders: Potential for significant value creation through the acquisition, including increased market share, revenue, and EPS growth. Urged to read proxy materials and vote on the proposed transaction.
• Employees: Risk of inability to retain and hire key personnel in the combined company. Potential for disruption due to the transaction's pendency.
• Customers: Potential for enhanced product offerings and service capabilities from the combined entity, particularly in high-growth adjacencies and multiplex diagnostics.
• Suppliers: Potential for disruption to relationships due to the transaction's pendency.
• Creditors: Risk of credit ratings decline for the combined company following the proposed transaction.

Next Steps

• Waters Corporation will present the investor presentation at the J.P. Morgan Healthcare Conference on January 12, 2026, followed by a Q&A session.
• A transcript of the presentation will be available on the Waters Corporation website in the Investors section.
• Investors and security holders are urged to read the proxy statement/prospectus, information statement, and any other documents filed or to be filed with the SEC regarding the proposed transaction.
• The parties involved will continue to work towards satisfying closing conditions and obtaining regulatory approvals for the proposed transaction.
• The combined company will focus on integrating the businesses of Waters and SpinCo to realize anticipated benefits and synergies.

Key Dates

Recommendation

The filing outlines a compelling strategic acquisition that is expected to significantly expand Waters' total addressable market, enhance its competitive position in high-growth segments, and deliver substantial financial synergies. The company's current financial performance is strong and outperforms peers, and the projected outlook for the combined entity indicates continued industry-leading growth in revenue, EBIT margin, and EPS. While integration risks exist, the clear strategic rationale, identified synergy targets, and robust financial projections suggest a strong upside potential for investors, warranting a 'strong buy' recommendation.

Keywords

Waters Corporation, Becton Dickinson, BD, Augusta SpinCo Corporation, SpinCo, J.P. Morgan Healthcare Conference, SEC Filing, 8-K, Investor Presentation, Acquisition, Merger, Life Sciences, Diagnostics, Analytical Instruments, Chromatography, Mass Spectrometry, Flow Cytometry, Microbiology, Financial Performance, Revenue Synergies, Cost Synergies, TAM Expansion, Biologics, GLP-1s, PFAS, India Generics